Interferon-beta/EMZ 701

Drug Profile

Interferon-beta/EMZ 701

Alternative Names: EMZ701 + interferon-β; IFN-β + EMZ701; Interferon-beta combination therapy - Transition Therapeutics; Interferon-enhancing therapy for multiple sclerosis - Transition Therapeutics; MS-I.E.T.

Latest Information Update: 23 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transition Therapeutics
  • Class
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 23 Nov 2006 Discontinued - Phase-II for Multiple sclerosis in Canada (unspecified route)
  • 01 Feb 2005 Transition Therapeutics has initiated enrolment in a phase II trial for multiple sclerosis in Canada
  • 01 Nov 2004 This therapy is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top